Leishmaniasis: current status of available drugs and new potential drug targets
Reads0
Chats0
TLDR
This review will initially describe current drug regimens and later will provide an overview on few important biochemical and enzymatic machineries that could be utilized as putative drug targets for generation of true antileishmanial drugs.About:
This article is published in Asian Pacific Journal of Tropical Medicine.The article was published on 2012-06-01 and is currently open access. It has received 347 citations till now. The article focuses on the topics: Miltefosine & Drug.read more
Citations
More filters
Journal ArticleDOI
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Mark C. Field,David Horn,Alan H. Fairlamb,Michael A. J. Ferguson,David W. Gray,Kevin D. Read,Manu De Rycker,Leah S. Torrie,Paul G. Wyatt,Susan Wyllie,Ian H. Gilbert +10 more
TL;DR: The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.
Journal ArticleDOI
Natural product based leads to fight against leishmaniasis.
TL;DR: Current drug regimens, putative drug targets, numerous natural products that have shown promising antileishmanial activity along with some key issues and strategies for future research to control leishmaniasis worldwide are described.
Journal ArticleDOI
Advances in Development of New Treatment for Leishmaniasis.
Juliana Perrone Bezerra de Menezes,Carlos Eduardo Sampaio Guedes,Antonio Luis de Oliveira Almeida Petersen,Deborah Bittencourt Mothé Fraga,Patrícia Sampaio Tavares Veras +4 more
TL;DR: How high-throughput analysis is helping the scientific community to identify novel targets for chemotherapeutic interventions and how this helped to identify and assess the potential of new identified targets is discussed.
Journal ArticleDOI
The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases
TL;DR: This review highlights the potential that remains untapped in natural products as drug leads for NTDs, and covers natural products from plant, marine, and microbial sources including natural-product-inspired semi-synthetic derivatives which have been evaluated against the various causative agents of N TDs.
Journal ArticleDOI
Cutaneous and mucocutaneous leishmaniasis : Differential diagnosis, diagnosis, histopathology, and management
TL;DR: The diagnosis of leishmaniasis can be challenging because it mimics both infectious and malignant conditions as discussed by the authors, and a misdiagnosis may lead to an unfavorable outcome, and appropriate management requires an accurate diagnosis, which often includes identification of the specific etiologic species.
References
More filters
Journal ArticleDOI
Leishmaniasis: current situation and new perspectives.
TL;DR: Research for leishmaniasis has been more and more focusing on the development of new tools such as diagnostic tests, drugs and vaccines, and the newly available control tools should allow a scaling up of control activities in priority areas.
Journal ArticleDOI
Drug Resistance in Leishmaniasis
TL;DR: It is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.
Journal ArticleDOI
The genome of the kinetoplastid parasite, Leishmania major.
Alasdair Ivens,Christopher S. Peacock,Elizabeth A. Worthey,Lee Murphy,Gautam Aggarwal,Matthew Berriman,Ellen Sisk,Marie-Adèle Rajandream,Ellen Adlem,Rita Aert,Atashi Anupama,Zina Apostolou,Philip Attipoe,Nathalie Bason,Christopher Bauser,Alfred Beck,Stephen M. Beverley,Gabriella Bianchettin,K. Borzym,G. Bothe,Carlo V. Bruschi,Carlo V. Bruschi,Matt Collins,Eithon Cadag,Laura Ciarloni,Christine Clayton,Richard M.R. Coulson,Ann Cronin,Angela K. Cruz,Robert L. Davies,Javier G. De Gaudenzi,Deborah E. Dobson,Andreas Duesterhoeft,Gholam Fazelina,Nigel Fosker,Alberto C.C. Frasch,Audrey Fraser,Monika Fuchs,Claudia Gabel,Arlette Goble,André Goffeau,David Harris,Christiane Hertz-Fowler,Helmut Hilbert,David Horn,Yiting Huang,Sven Klages,Andrew J Knights,Michael Kube,Natasha Larke,Lyudmila Litvin,Angela Lord,Tin Louie,Marco A. Marra,David Masuy,Keith R. Matthews,Shulamit Michaeli,Jeremy C. Mottram,Silke Müller-Auer,Heather Munden,Siri Nelson,Halina Norbertczak,Karen Oliver,Susan O'Neil,Martin Pentony,Thomas M. Pohl,Claire Price,Bénédicte Purnelle,Michael A. Quail,Ester Rabbinowitsch,Richard Reinhardt,Michael A. Rieger,Joel Rinta,Johan Robben,Laura Robertson,Jeronimo C. Ruiz,Simon Rutter,David L. Saunders,Melanie Schäfer,Jacquie Schein,David C. Schwartz,Kathy Seeger,Amber Seyler,Sarah Sharp,Heesun Shin,Dhileep Sivam,Rob Squares,Steve Squares,Valentina Tosato,Christy Vogt,Guido Volckaert,Rolf Wambutt,T. Warren,Holger Wedler,John Woodward,Shiguo Zhou,Wolfgang Zimmermann,Deborah F. Smith,Jenefer M. Blackwell,Kenneth Stuart,Kenneth Stuart,Bart Barrell,Peter J. Myler,Peter J. Myler +103 more
TL;DR: The organization of protein-coding genes into long, strand-specific, polycistronic clusters and lack of general transcription factors in the L. major, Trypanosoma brucei, and Tritryp genomes suggest that the mechanisms regulating RNA polymerase II–directed transcription are distinct from those operating in other eukaryotes, although the trypanosomatids appear capable of chromatin remodeling.
Journal ArticleDOI
Structure-based strategies for drug design and discovery.
TL;DR: The combination of molecular structure determination and computation is emerging as an important tool for drug development and will be applied to acquired immunodeficiency syndrome (AIDS) and bacterial drug resistance.
Journal ArticleDOI
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Simon L. Croft,Graham H. Coombs +1 more
TL;DR: The immunomodulator imiquimod has proved to be an adjunct for CL therapy and the search for new drugs continues, with bisphosphonates, for example, risedronate and pamidronate, and plant derivatives being reported to have activity against experimental animal infections.